Royce & Associates LP Sells 29,768 Shares of Eagle Pharmaceuticals Inc (EGRX)

Share on StockTwits

Royce & Associates LP decreased its stake in Eagle Pharmaceuticals Inc (NASDAQ:EGRX) by 42.5% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 40,275 shares of the specialty pharmaceutical company’s stock after selling 29,768 shares during the period. Royce & Associates LP owned 0.27% of Eagle Pharmaceuticals worth $3,047,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently modified their holdings of the company. Meeder Asset Management Inc. increased its stake in shares of Eagle Pharmaceuticals by 232.6% in the second quarter. Meeder Asset Management Inc. now owns 1,866 shares of the specialty pharmaceutical company’s stock valued at $141,000 after buying an additional 1,305 shares during the period. Piedmont Investment Advisors LLC bought a new stake in shares of Eagle Pharmaceuticals during the 2nd quarter valued at about $150,000. US Bancorp DE boosted its position in shares of Eagle Pharmaceuticals by 191.9% during the 2nd quarter. US Bancorp DE now owns 2,767 shares of the specialty pharmaceutical company’s stock valued at $209,000 after purchasing an additional 1,819 shares in the last quarter. Crossmark Global Holdings Inc. bought a new stake in shares of Eagle Pharmaceuticals during the 2nd quarter valued at about $251,000. Finally, Louisiana State Employees Retirement System bought a new stake in shares of Eagle Pharmaceuticals during the 2nd quarter valued at about $280,000.

Several equities research analysts recently commented on EGRX shares. upped their target price on Eagle Pharmaceuticals to $119.00 and gave the company a “buy” rating in a research report on Tuesday, July 3rd. Cantor Fitzgerald started coverage on Eagle Pharmaceuticals in a research report on Monday, June 11th. They set an “overweight” rating and a $81.00 target price on the stock. Piper Jaffray Companies set a $86.00 target price on Eagle Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, July 24th. Zacks Investment Research upgraded Eagle Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Wednesday, June 13th. Finally, Mizuho restated an “underperform” rating and set a $54.00 target price on shares of Eagle Pharmaceuticals in a research report on Thursday, May 17th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $86.67.

Shares of Eagle Pharmaceuticals stock opened at $68.63 on Thursday. Eagle Pharmaceuticals Inc has a one year low of $48.84 and a one year high of $85.66. The company has a debt-to-equity ratio of 0.22, a quick ratio of 4.09 and a current ratio of 4.22. The stock has a market cap of $1.04 billion, a P/E ratio of 20.36 and a beta of 1.31.

Eagle Pharmaceuticals (NASDAQ:EGRX) last announced its earnings results on Tuesday, August 7th. The specialty pharmaceutical company reported $0.95 EPS for the quarter, beating the consensus estimate of $0.80 by $0.15. Eagle Pharmaceuticals had a return on equity of 19.71% and a net margin of 13.81%. The company had revenue of $59.30 million for the quarter, compared to analyst estimates of $51.78 million. equities research analysts expect that Eagle Pharmaceuticals Inc will post 2.15 earnings per share for the current fiscal year.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers argatroban for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; non-alcohol docetaxel injection, a chemotherapeutic agent for breast, non-small cell lung, prostate, head, and neck cancers/gastric adenocarcinoma; and Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL).

Read More: What is the NASDAQ Stock Market?

Want to see what other hedge funds are holding EGRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eagle Pharmaceuticals Inc (NASDAQ:EGRX).

Institutional Ownership by Quarter for Eagle Pharmaceuticals (NASDAQ:EGRX)

Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply